The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, --C(O)R.sub.5, nitro, --NR.sub.6R.sub.7, cyano, and a group R.sub.8; R.sub.1 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR.sub.6R.sub.7 or cyano; R.sub.2 is hydrogen, C3-C7 cycloalkyl, or a group R.sub.9; R.sub.3 is C3-C7 cycloalkyl, or a group R.sub.9; or R.sub.2 and R.sub.3 together with N form a 5-14 membered heterocycle, which may be substituted by 1 to 3 R.sub.10 groups; R.sub.4 is hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl; R.sub.5 is a C1-C4 alkyl, --OR.sub.6 or --NR.sub.6R.sub.7; R.sub.6 is hydrogen or C1-C6 alkyl; R.sub.7 is hydrogen or C1-C6 alkyl; R.sub.8 is a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more R.sub.11 groups; R.sub.9 is a C1-C6 alkyl that may be substituted by one or more groups selected from: C3-C7 cycloalkyl, C1-C6 alkoxy, haloC1-C6 alkoxy, hydroxy, haloC1-C6 alkyl; R.sub.10 is a group R.sub.8, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, C(O)NR.sub.6R.sub.7, phenyl which may be substituted by 1 to 4 R.sub.11 groups; R.sub.11 is C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, or C(O)NR.sub.6R.sub.7; X is carbon or nitrogen; n is 1 or 2; to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).